TQH2929 / Sino Biopharm - LARVOL DELTA

A Clinical Study of TQH2929 Injection in Treatment With Generalized Pustular Psoriasis (GPP) (clinicaltrials.gov) - P1 | N=9 | Active, not recruiting | Sponsor: Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Recruiting ➔ Active, not recruiting | Trial completion date: Feb 2025 ➔ Dec 2025 | Trial primary completion date: Feb 2025 ➔ Jul 2025

Enrollment closed • Trial completion date • Trial primary completion date • Dermatology • Immunology • Psoriasis • Pustular Psoriasis

A Clinical Study of TQH2929 in Healthy Adult Subjects (clinicaltrials.gov) - P1 | N=40 | Completed | Sponsor: Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Active, not recruiting ➔ Completed

Trial completion • Dermatology • Immunology • Psoriasis

A Clinical Study of TQH2929 in Healthy Adult Subjects (clinicaltrials.gov) - P1 | N=40 | Active, not recruiting | Sponsor: Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Recruiting ➔ Active, not recruiting | N=78 ➔ 40 | Trial primary completion date: Jan 2025 ➔ Aug 2024

Enrollment change • Enrollment closed • Trial primary completion date • Dermatology • Immunology • Psoriasis

A Clinical Study of TQH2929 Injection in Treatment With Generalized Pustular Psoriasis (GPP) (clinicaltrials.gov) - P1 | N=10 | Recruiting | Sponsor: Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Not yet recruiting ➔ Recruiting

Enrollment open • Dermatology • Immunology • Psoriasis • Pustular Psoriasis

A Clinical Study of TQH2929 Injection in Treatment With Generalized Pustular Psoriasis (GPP) (clinicaltrials.gov) - P1 | N=10 | Not yet recruiting | Sponsor: Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.

New P1 trial • Dermatology • Immunology • Psoriasis • Pustular Psoriasis

A Clinical Study of TQH2929 in Healthy Adult Subjects (clinicaltrials.gov) - P1 | N=78 | Recruiting | Sponsor: Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.

New P1 trial • Dermatology • Immunology • Psoriasis